Chronic Lymphocytic Leukaemia
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
150%
Monoclonal Antibody
150%
Competitive Landscape
2 companies ranked by most advanced pipeline stage
CP
GS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Chugai PharmaOfatumumab
Gilead SciencesIdelalisib
Clinical Trials (2)
Total enrollment: 782 patients across 2 trials
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment
Start: Dec 2011Est. completion: Dec 2017670 patients
Phase 3Unknown
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
Start: Sep 2018Est. completion: Mar 2019112 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
Small Molecule is the dominant modality (50% of programs)
2 companies competing in this space